{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T22:59:32Z","timestamp":1788994772650,"version":"build-2803163510"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Circulation"],"published-print":{"date-parts":[[2001,2,6]]},"abstract":"<jats:p>\n                    <jats:italic>Background<\/jats:italic>\n                    \u2014Subcutaneous low-molecular-weight (LMW) heparins can effectively replace unfractionated heparin in patients with unstable angina or non\u2013Q-wave myocardial infarction. However, the optimal anticoagulation strategy for these patients when they require cardiac catheterization is still unclear. Therefore, we evaluated a new and simple strategy of anticoagulation in these patients.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:italic>Methods and Results<\/jats:italic>\n                    \u2014A total of 451 consecutive patients with unstable angina\/non\u2013Q-wave myocardial infarction were treated for at least 48 hours with subcutaneous injections of enoxaparin (1 mg [100 IU]\/kg every 12 hours, cycled at 6 AM and 6 PM). Of this unselected population, 293 patients (65%) underwent a coronary angiography within 8 hours of the morning LMW heparin injection, followed by immediate percutaneous coronary intervention (PCI) in 132 patients (28%). PCI was performed without any additional bolus of unfractionated\/LMW heparin and without coagulation monitoring. Anti-Xa activity at the time of catheterization was 0.98\u00b10.03 IU\/mL, was &gt;0.5 IU\/mL in 97.6% of patients, and did not relate to the LMW heparin injection-to-catheterization time. There were no in-hospital abrupt closures or urgent revascularizations after PCI. The death\/myocardial infarction rate at 30 days was 3.0% in the PCI group (n=132) but 6.2% in the whole population (n=451) and 10.8% in the patients not undergoing catheterization (n=158). The 30-day major bleeding rate was 0.8% in the PCI group, which was comparable to that of patients without catheterization (1.3%).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:italic>Conclusions<\/jats:italic>\n                    \u2014PCI within 8 hours of the last enoxaparin subcutaneous injection seems to be safe and effective. The safety of subcutaneous LMW heparin in combination with platelet glycoprotein IIb\/IIIa blockade awaits further study.\n                  <\/jats:p>","DOI":"10.1161\/01.cir.103.5.658","type":"journal-article","created":{"date-parts":[[2012,6,11]],"date-time":"2012-06-11T20:09:32Z","timestamp":1339445372000},"page":"658-663","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":171,"title":["Percutaneous Coronary Intervention After Subcutaneous Enoxaparin Pretreatment in Patients With Unstable Angina Pectoris"],"prefix":"10.1161","volume":"103","author":[{"given":"J. Ph.","family":"Collet","sequence":"first","affiliation":[{"name":"From the Department of Cardiology and the Hemostasis Laboratory (A.A.), Pitie\u0301-Salpe\u0302trie\u0300re University Hospital, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Montalescot","sequence":"additional","affiliation":[{"name":"From the Department of Cardiology and the Hemostasis Laboratory (A.A.), Pitie\u0301-Salpe\u0302trie\u0300re University Hospital, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Lison","sequence":"additional","affiliation":[{"name":"From the Department of Cardiology and the Hemostasis Laboratory (A.A.), Pitie\u0301-Salpe\u0302trie\u0300re University Hospital, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Choussat","sequence":"additional","affiliation":[{"name":"From the Department of Cardiology and the Hemostasis Laboratory (A.A.), Pitie\u0301-Salpe\u0302trie\u0300re University Hospital, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ankri","sequence":"additional","affiliation":[{"name":"From the Department of Cardiology and the Hemostasis Laboratory (A.A.), Pitie\u0301-Salpe\u0302trie\u0300re University Hospital, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Drobinski","sequence":"additional","affiliation":[{"name":"From the Department of Cardiology and the Hemostasis Laboratory (A.A.), Pitie\u0301-Salpe\u0302trie\u0300re University Hospital, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Sotirov","sequence":"additional","affiliation":[{"name":"From the Department of Cardiology and the Hemostasis Laboratory (A.A.), Pitie\u0301-Salpe\u0302trie\u0300re University Hospital, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Thomas","sequence":"additional","affiliation":[{"name":"From the Department of Cardiology and the Hemostasis Laboratory (A.A.), Pitie\u0301-Salpe\u0302trie\u0300re University Hospital, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_2_1_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199708143370702"},{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.100.15.1593"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.100.15.1602"},{"key":"e_1_3_2_4_2","unstructured":"Deutsch E Cohen M Radley DR et al. Safety and efficacy of percutaneous procedures in patients receiving subcutaneous enoxaparin for unstable angina: results of the ESSENCE trial. Circulation. 1998;98(suppl I):1563. Abstract."},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008943529597"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)07349-3"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.97.3.251"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1053\/euhj.1998.1047"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(96)00343-9"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(99)00582-2"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.94.5.911"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(97)00094-6"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.101.10.1083"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.98.4.294"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(00)00695-1"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)10452-9"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.90.2.8044962"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.94.7.1553"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.96.10.3396"},{"key":"e_1_3_2_20_2","unstructured":"Kereiakes DJ Fry E Matthai W et al. Combination enoxaparin and abciximab therapy during percutaneous coronary intervention: \u201cNICE\u201d guys finish first. J Invas Cardiol. 2000;12(suppl):1A\u20135A."},{"key":"e_1_3_2_21_2","doi-asserted-by":"crossref","unstructured":"Kereiakes DJ McDonald MA Broderick TM et al. Platelet glycoprotein IIb\/IIIa receptor blockers: an appropriate use model for expediting care in acute coronary syndromes. Am Heart J. 2000;139(suppl):S53\u2013S60.","DOI":"10.1067\/mhj.2000.103741"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(99)00643-9"}],"container-title":["Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/01.CIR.103.5.658","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,12]],"date-time":"2024-05-12T09:08:08Z","timestamp":1715504888000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/01.CIR.103.5.658"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,2,6]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2001,2,6]]}},"alternative-id":["10.1161\/01.CIR.103.5.658"],"URL":"https:\/\/doi.org\/10.1161\/01.cir.103.5.658","relation":{},"ISSN":["0009-7322","1524-4539"],"issn-type":[{"value":"0009-7322","type":"print"},{"value":"1524-4539","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,2,6]]},"assertion":[{"value":"2001-02-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}